Calluna Pharma Completes Dosing in Phase II AURORA Trial for Idiopathic Pulmonary Fibrosis
Wednesday, 14 October 2026, 01:48
Overview of Phase II AURORA Trial
Calluna Pharma has successfully completed patient dosing in the Phase II AURORA trial of CAL101 aimed at treating idiopathic pulmonary fibrosis (IPF). This condition represents a serious threat to respiratory health and affects many individuals globally.
Purpose of the AURORA Trial
The AURORA trial seeks to determine the efficacy of CAL101 in improving lung function among patients diagnosed with IPF.
Next Steps After Dosing Completion
- Monitor patient progress closely.
- Evaluate medication efficacy.
- Transition into final follow-up phase.
This phase is crucial as it will inform the future of treatment options available for IPF.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.